Our data support that the mitochondrial damaging effect of MKIs, such as sorafenib and regorafenib, is promoting mitophagy in hepatoma cells, being the PINK1/Parkin signaling pathway clearly enhanced by modifying the antioxidant defense, as BSO pre-incubation does. This evidence concerns the gene PRKN and hepatocellular carcinoma.